+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Brazil Radiopharmaceuticals Market By Radioisotope, By Application, By Type, By End User: Opportunity Analysis and Industry Forecast, 2023-2032

  • PDF Icon

    Report

  • 76 Pages
  • May 2023
  • Region: Brazil
  • Allied Market Research
  • ID: 5916377
UP TO OFF until Oct 24th 2024
The radiopharmaceuticals market in Brazil is anticipated to experience considerable development over the forecast period. The market is witnessing a surge for radiopharmaceuticals due to factors such as increased prevalence of cancer, growing investments in the healthcare field, and increased access to healthcare in Brazil. The Brazil radiopharmaceuticals market is also attracting focus of foreign players, causing a high competition in the market.

The federal government initiatives to improve public access to healthcare, increase medical care investing, and concentrate on healthcare digitization are raising the uptake of radiopharmaceuticals in the Brazilian market. Moreover, the high number of people suffering from chronic diseases like cancer and the growing need for customized medication are anticipated to drive the market. Additionally, technological improvements and the introduction of new radiopharmaceuticals such as technetium-99m are driving the growth of the market.

Opportunities for the Brazil radiopharmaceuticals market include the advancement in treatment alternatives for chronic diseases, such as cancer cell immunotherapy and targeted radiotherapy. Furthermore, technological improvements in imaging have made it much easier to identify cancer cells and lump sites, resulting in more target-specific therapy. Additionally, the introduction of new radiopharmaceuticals with minimal side effects and improved efficacy has made it possible for market players to expand their product portfolio and venture into untapped sectors in the market. Furthermore, partnerships between universities, government bodies, and clinical research institutes can result in the advancement of innovative products and enhance market penetration.

Despite the driving factors, the market is limited by the high cost of radiopharmaceuticals, absence of knowledge and skilled personnel for production as well as handling of radioisotopes. Furthermore, there are stringent guidelines in radiopharmaceutical production as well as handling of radiopharmaceuticals in Brazil. Rising investments in the medical care industry and boosting public access to healthcare are expected to result in tremendous opportunities for the Brazil radiopharmaceuticals market in the future. Additionally, the introduction of more advanced radiopharmaceuticals will provide significant opportunities for the market players. For example, the introduction of fluorine-18 and gallium-68 radioisotopes over the last few years will certainly create high investment opportunities for the Brazil radiopharmaceuticals market.

The need for radiopharmaceuticals in the Brazilian market is anticipated to keep propelling throughout the forecast duration. This is attributed to the expanding financial investments in the medical care industry, federal government initiatives, and increasing public awareness pertaining to health care in Brazil. Additionally, the new and more advanced radioisotopes such as technetium-99m, iodine-I, and also gallium-68 are expected to be increasingly utilized in the Brazilian market. Additionally, a rise in the number of cancer patients and the emerging trend of tailored medication will contribute to the growth of the Brazil radiopharmaceuticals market.

The Brazil radiopharmaceuticals market is segmented based upon the radioisotope, application, and end user. Based on radioisotope, the market is divided into technetium 99m, fluorine 18, iodine I, gallium 68, and others. Based on application, the market is divided into cancer, cardiology, and others. Based on type, the market is divided into diagnostic and therapeutic. Based on end user, the market is divided into hospitals & clinics, medical imaging centers, and others.

The Brazil radiopharmaceuticals market is witnessing growth with high investments in the medical care field as well as growing public awareness of medical care in the nation. The increasing number of cancer patients as well as the growing demand for individualized medicine will certainly create a raised need for radiopharmaceuticals in Brazil. Additionally, new as well as advanced radiopharmaceuticals are expected to be progressively made use of in the Brazilian market. The high number of health centers as well as facilities with sophisticated equipment will promote the growth of the Brazil radiopharmaceuticals market.

The high influx of cancer patients is expected to cause significant expansion in the Brazil radiopharmaceuticals market over the course of the forecast period. In addition, financial investments from the government in healthcare framework and the introduction of brand-new radiopharmaceuticals with improved efficiency are expected to fuel the development of the market in the country. The northern region of Brazil is expected to be the fastest-growing market throughout the forecast period, attributable to the desirable reimbursement policies and the number of medical care centers in the region.

The Porter’s five forces analysis of the Brazil radiopharmaceuticals market is a helpful tool to assess the degree of competition as well as attractiveness of the market. The negotiating power of customers in the Brazil radiopharmaceuticals market is high, as there is low switching expense as well as high accessibility to the purchasers in the market. Additionally, the bargaining power of distributors in the Brazil radiopharmaceuticals market is high, owing to minimal capital expense as well as great understanding of the market to the vendors. The competitive rivalry in the Brazil radiopharmaceuticals market is high because of the existence of various players offering competitive products.

Key Benefits For Stakeholders

Enabled informed decision-making process and market analysis based on current market situation and estimated future trends.

Analysis of the key strategies adopted by major market players in Brazil radiopharmaceuticals market.
  • Assess and rank the top factors that are expected to affect the growth of Brazil radiopharmaceuticals market.
  • Top Player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the Brazil radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
  • Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • New Product Development/ Product Matrix of Key Players
  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Type

  • Diagnostic
  • Therapeutic

By End User

  • Hospitals and clinics
  • Medical Imaging centers
  • Others

By Radioisotope

  • Fluorine 18
  • Iodine I
  • Gallium 68
  • Others
  • Technetium 99m

By Application

  • Cancer
  • Cardiology
  • Others
  • Key Market Players
  • BRABCOOK Pharmaceuticals
  • Cristália
  • AROMAR
  • National Radiopharmaceuticals
  • Buclizine
  • Anadigm
  • ALLERGAN Groups
  • Gama Medica
  • FcSm
  • Zepp Online Laboratories

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: BRAZIL RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.2. Technetium 99m
4.3. Fluorine 18
4.4. Iodine I
4.5. Gallium 68
4.6. Others
CHAPTER 5: BRAZIL RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.2. Cancer
5.3. Cardiology
5.4. Others
CHAPTER 6: BRAZIL RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.2. Diagnostic
6.3. Therapeutic
CHAPTER 7: BRAZIL RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.2. Hospitals and clinics
7.3. Medical Imaging centers
7.4. Others
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. BRABCOOK Pharmaceuticals
9.2. Cristália
9.3. AROMAR
9.4. National Radiopharmaceuticals
9.5. Buclizine
9.6. Anadigm
9.7. ALLERGAN Groups
9.8. Gama Medica
9.9. FcSm
9.10. Zepp Online Laboratories
List of Tables
Table 01. Brazil Radiopharmaceuticals Market, by Radioisotope, 2022-2032 ($ Million)
Table 02. Brazil Radiopharmaceuticals Market, by Application, 2022-2032 ($ Million)
Table 03. Brazil Radiopharmaceuticals Market, by Type, 2022-2032 ($ Million)
Table 04. Brazil Radiopharmaceuticals Market, by End-user, 2022-2032 ($ Million)
Table 05. Brabcook Pharmaceuticals: Key Executives
Table 06. Brabcook Pharmaceuticals: Company Snapshot
Table 07. Brabcook Pharmaceuticals: Operating Segments
Table 08. Brabcook Pharmaceuticals: Product Portfolio
Table 09. Brabcook Pharmaceuticals: Key Stratergies
Table 10. Cristália: Key Executives
Table 11. Cristália: Company Snapshot
Table 12. Cristália: Operating Segments
Table 13. Cristália: Product Portfolio
Table 14. Cristália: Key Stratergies
Table 15. Aromar: Key Executives
Table 16. Aromar: Company Snapshot
Table 17. Aromar: Operating Segments
Table 18. Aromar: Product Portfolio
Table 19. Aromar: Key Stratergies
Table 20. National Radiopharmaceuticals: Key Executives
Table 21. National Radiopharmaceuticals: Company Snapshot
Table 22. National Radiopharmaceuticals: Operating Segments
Table 23. National Radiopharmaceuticals: Product Portfolio
Table 24. National Radiopharmaceuticals: Key Stratergies
Table 25. Buclizine: Key Executives
Table 26. Buclizine: Company Snapshot
Table 27. Buclizine: Operating Segments
Table 28. Buclizine: Product Portfolio
Table 29. Buclizine: Key Stratergies
Table 30. Anadigm: Key Executives
Table 31. Anadigm: Company Snapshot
Table 32. Anadigm: Operating Segments
Table 33. Anadigm: Product Portfolio
Table 34. Anadigm: Key Stratergies
Table 35. Allergan Groups: Key Executives
Table 36. Allergan Groups: Company Snapshot
Table 37. Allergan Groups: Operating Segments
Table 38. Allergan Groups: Product Portfolio
Table 39. Allergan Groups: Key Stratergies
Table 40. Gama Medica: Key Executives
Table 41. Gama Medica: Company Snapshot
Table 42. Gama Medica: Operating Segments
Table 43. Gama Medica: Product Portfolio
Table 44. Gama Medica: Key Stratergies
Table 45. Fcsm: Key Executives
Table 46. Fcsm: Company Snapshot
Table 47. Fcsm: Operating Segments
Table 48. Fcsm: Product Portfolio
Table 49. Fcsm: Key Stratergies
Table 50. Zepp Online Laboratories: Key Executives
Table 51. Zepp Online Laboratories: Company Snapshot
Table 52. Zepp Online Laboratories: Operating Segments
Table 53. Zepp Online Laboratories: Product Portfolio
Table 54. Zepp Online Laboratories: Key Stratergies
List of Figures
Figure 01. Brazil Radiopharmaceuticals Market, 2022-2032
Figure 02. Segmentation of Brazil Radiopharmaceuticals Market, 2022-2032
Figure 03. Top Investment Pockets in Brazil Radiopharmaceuticals Market (2023-2032)
Figure 04. Porter's Five - 1
Figure 05. Porter's Five - 2
Figure 06. Porter's Five - 3
Figure 07. Porter's Five - 4
Figure 08. Porter's Five - 5
Figure 09. Drivers, Restraints and Opportunities: Brazil Radiopharmaceuticals Market
Figure 10. Brazil Radiopharmaceuticals Market,By Radioisotope, 2022 ($ Million)
Figure 11. Brazil Radiopharmaceuticals Market,By Application, 2022 ($ Million)
Figure 12. Brazil Radiopharmaceuticals Market,By Type, 2022 ($ Million)
Figure 13. Brazil Radiopharmaceuticals Market,By End-user, 2022 ($ Million)
Figure 14. Top Winning Strategies, by Year
Figure 15. Top Winning Strategies, by Development
Figure 16. Top Winning Strategies, by Company
Figure 17. Product Mapping of Top 10 Players
Figure 18. Competitive Dashboard
Figure 19. Competitive Heatmap: Brazil Radiopharmaceuticals Market
Figure 20. Top Player Positioning, 2022
Figure 21. Brabcook Pharmaceuticals: Net Sales, 2020-2022* ($ Million)
Figure 22. Brabcook Pharmaceuticals: Revenue Share, by Segment, 2022 (%)
Figure 23. Brabcook Pharmaceuticals: Revenue Share, by Geography, 2022 (%)
Figure 24. Cristália: Net Sales, 2020-2022* ($ Million)
Figure 25. Cristália: Revenue Share, by Segment, 2022 (%)
Figure 26. Cristália: Revenue Share, by Geography, 2022 (%)
Figure 27. Aromar: Net Sales, 2020-2022* ($ Million)
Figure 28. Aromar: Revenue Share, by Segment, 2022 (%)
Figure 29. Aromar: Revenue Share, by Geography, 2022 (%)
Figure 30. National Radiopharmaceuticals: Net Sales, 2020-2022* ($ Million)
Figure 31. National Radiopharmaceuticals: Revenue Share, by Segment, 2022 (%)
Figure 32. National Radiopharmaceuticals: Revenue Share, by Geography, 2022 (%)
Figure 33. Buclizine: Net Sales, 2020-2022* ($ Million)
Figure 34. Buclizine: Revenue Share, by Segment, 2022 (%)
Figure 35. Buclizine: Revenue Share, by Geography, 2022 (%)
Figure 36. Anadigm: Net Sales, 2020-2022* ($ Million)
Figure 37. Anadigm: Revenue Share, by Segment, 2022 (%)
Figure 38. Anadigm: Revenue Share, by Geography, 2022 (%)
Figure 39. Allergan Groups: Net Sales, 2020-2022* ($ Million)
Figure 40. Allergan Groups: Revenue Share, by Segment, 2022 (%)
Figure 41. Allergan Groups: Revenue Share, by Geography, 2022 (%)
Figure 42. Gama Medica: Net Sales, 2020-2022* ($ Million)
Figure 43. Gama Medica: Revenue Share, by Segment, 2022 (%)
Figure 44. Gama Medica: Revenue Share, by Geography, 2022 (%)
Figure 45. Fcsm: Net Sales, 2020-2022* ($ Million)
Figure 46. Fcsm: Revenue Share, by Segment, 2022 (%)
Figure 47. Fcsm: Revenue Share, by Geography, 2022 (%)
Figure 48. Zepp Online Laboratories: Net Sales, 2020-2022* ($ Million)
Figure 49. Zepp Online Laboratories: Revenue Share, by Segment, 2022 (%)
Figure 50. Zepp Online Laboratories: Revenue Share, by Geography, 2022 (%)

Companies Mentioned

  • BRABCOOK Pharmaceuticals
  • Cristália
  • AROMAR
  • National Radiopharmaceuticals
  • Buclizine
  • Anadigm
  • ALLERGAN Groups
  • Gama Medica
  • FcSm
  • Zepp Online Laboratories

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...